BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report) fell 3.8% on Tuesday . The stock traded as low as C$10.60 and last traded at C$10.60. 3,402 shares were traded during mid-day trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Stock Down 3.8%
The company has a debt-to-equity ratio of 0.05, a quick ratio of 128.68 and a current ratio of 129.63. The firm has a market cap of C$168.68 million and a PE ratio of -28.19. The stock has a fifty day moving average price of C$10.60 and a 200-day moving average price of C$10.60.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
Read More
- Five stocks we like better than BriaCell Therapeutics
- What Does a Stock Split Mean?
- Why Taiwan Semiconductor’s 6.5% Dip Could Be a Smart Buy
- How to trade using analyst ratings
- RTX Surges to Record Highs as Defense Orders Explode
- How to start investing in penny stocks
- Smart Money Is Buying Auto Suppliers, Not Car Brands
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
